Baird raised the firm’s price target on LivaNova to $62 from $56 and keeps an Outperform rating on the shares. The firm sees potential for continued upside in 2H23 especially as new products roll out (Essenz) and growth trends in neuromod remain strong.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LIVN: